| Previous Close | 3.7200 |
| Open | 3.7100 |
| Bid | 3.6000 x 0 |
| Ask | 3.6100 x 0 |
| Day's Range | 3.4600 - 3.7100 |
| 52 Week Range | 1.8100 - 6.0600 |
| Volume | 164,388 |
| Avg. Volume | 335,203 |
| Market Cap | 191.023M |
| Beta (5Y Monthly) | 1.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5600 |
| Earnings Date | Mar. 05, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.75 |
- Simply Wall St.
Here's Why We're Not Too Worried About Oncolytics Biotech's (TSE:ONC) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Baystreet
Stocks in play: Oncolytics Biotech ® Inc.
Recently announced preclinical data highlighting pelareorep's ability to synergize with multiple classes ...
- CNW Group
Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), together with SOLTI, recently announced new clinical data from the AWARE-1 window-of-opportunity breast cancer study showing patients receiving pelareorep plus checkpoint blockade therapy met the trial's primary endpoint. These data are featured in an electronic poster at the American Association for Cancer Research (AACR) Annual Meeting 2021 during Week 1, which is taking place virtually from April 10-15, 2021.
© 2021 Verizon Media. All rights reserved.
